Insulin resistance contributes to the pathogenesis of several disease states including obesity and type 2 diabetes mellitus . We have investigated the nature of the genetic factors that predipose to the development of insulin resistance. Previously, we have identified mutations in the insulin receptor gene in patients with several genetic syndromes associated with insulin resistance. More recently, we have been carrying out clinical investigation of patients with various forms of lipoatrophy, most of whom also have insulin resistant diabetes. In collaboration with Drs. A. Garg and A. Bowcock (Univ. Texas Southwestern), the gene for congenital generalized lipoatrophy has been mapped to chromosome 9q34. In addition, we have demonstrated that troglitazone therapy dramatically improves metabolic control in patients with lipoatrophic diabetes. In the course of follow-up, we will also determine whether troglitazone leads to an increase in body fat. Efforts are underway to develop new protocols to evaluate the potential benefit of newer therapeutic agents (including rosiglitazone, pioglitazone, and leptin). - insulin, insulin resistance, insulin receptor, tyrosine phosphorylation, diabetes, lipoatrophy, Dunnigan's syndrome, troglitazone - Human Subjects

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Intramural Research (Z01)
Project #
1Z01DK047022-20
Application #
6289799
Study Section
Special Emphasis Panel (DB)
Project Start
Project End
Budget Start
Budget End
Support Year
20
Fiscal Year
1999
Total Cost
Indirect Cost
City
State
Country
United States
Zip Code
Javor, Edward D; Moran, Stephanie Ann; Young, Janice Ryan et al. (2004) Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab 89:3199-207
Musso, Carla; Cochran, Elaine; Moran, Stephanie Ann et al. (2004) Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore) 83:209-22
Moran, Stephanie Ann; Patten, Nicole; Young, Janice Ryan et al. (2004) Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism 53:513-9
Cochran, Elaine; Young, Janice Ryan; Sebring, Nancy et al. (2004) Efficacy of recombinant methionyl human leptin therapy for the extreme insulin resistance of the Rabson-Mendenhall syndrome. J Clin Endocrinol Metab 89:1548-54
Agarwal, Anil K; Simha, Vinaya; Oral, Elif Arioglu et al. (2003) Phenotypic and genetic heterogeneity in congenital generalized lipodystrophy. J Clin Endocrinol Metab 88:4840-7
Gorden, Phillip; Gavrilova, Oksana (2003) The clinical uses of leptin. Curr Opin Pharmacol 3:655-9
Oral, Elif Arioglu; Ruiz, Elaine; Andewelt, Alexa et al. (2002) Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. J Clin Endocrinol Metab 87:3110-7
Petersen, Kitt Falk; Oral, Elif Arioglu; Dufour, Sylvie et al. (2002) Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 109:1345-50
Bolan, Charles; Oral, Elif Arioglu; Gorden, Phillip et al. (2002) Intensive, long-term plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy. J Clin Endocrinol Metab 87:380-4
Oral, Elif Arioglu; Simha, Vinaya; Ruiz, Elaine et al. (2002) Leptin-replacement therapy for lipodystrophy. N Engl J Med 346:570-8

Showing the most recent 10 out of 15 publications